Allows Patients With Exceptional Early Responses To Double Treatment Interval With Guselkumab With No Loss In Disease Control, Trial Shows. August 06, 2024 edition of American Academy of Dermatology’s Dermatology Daily
Allows Patients With Exceptional Early Responses To Double Treatment Interval With Guselkumab With No Loss In Disease Control, Trial Shows. August 06, 2024 edition of American Academy of Dermatology’s Dermatology Daily